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Abstract: Objective: To present an updated, comprehensive review on clinical and pre-clinical studies on agomelatine.  
Method: A MEDLINE, Psycinfo and Web of Science search (1966-May 2009) was performed using the following   
keywords: agomelatine, melatonin, S20098, efficacy, safety, adverse effect, pharmacokinetic, pharmacodynamic, major 
depressive disorder, bipolar disorder, Seasonal Affective Disorder (SAD), Alzheimer, ADHD, Generalized Anxiety   
Disorder (GAD), Panic Disorder (PD), Obsessive-Compulsive Disorder (OCD), anxiety disorders and mood disorder.  
Study collection and data extraction: All articles in English identified by the data sources were evaluated. Randomized, 
controlled clinical trials involving humans were prioritized in the review. The physiological bases of melatonergic   
transmission were also examined to deepen the clinical comprehension of agomelatine’ melatonergic modulation.  
Data synthesis: Agomelatine, a melatonergic analogue drug acting as MT1/MT2 agonist and 5-HT2C antagonist, has been 
reported to be an effective antidepressant therapy.  
Conclusions: Although a bias in properly assessing the “sleep core” of depression may still exist with current screening 
instruments, therefore making difficult to compare agomelatine’ efficacy to other antidepressant ones, comparative studies 
showed agomelatine to be an intriguing option for depression and, potentially, for other therapeutic targets as well. 
Keywords: Agomelatine, melatonin, depression, mood, cognition, Alzheimer, bipolar disorder.  
INTRODUCTION 
  The definition of depression essentially relies on de-
pressed mood. Yet, depression represents a multi-
dimensional condition. Among others, psychomotor symp-
toms, sleep disturbances, somatic, pain symptoms, anxiety, 
diurnal variation and seasonal patterns, could lead to very 
heterogeneous pictures, possibly underpined by different 
pathogenetic mechanism [1]. Hence, the associate burden 
may vary as well. Furthermore, Mood Disorders (MDs), par-
ticularly Major Depressive Disorder (MDD), are spread 
among general population, both with sub- and full-threshold 
manifestations: MDD has been estimated to be the fourth 
major cause of disability worldwide, and may become sec-
ond only to cardiovascular diseases by around 2020 [2]. Al-
though the social relevance of the phenomenon, less than 
50% of all patients treated with the currently available anti-
depressants show full remission [3], with a large number of 
subjects showing residual and relapsing symptoms [4] and 
general poor antidepressant outcome still in a too high num-
ber of cases as demonstrated by the Sequenced Treatment 
Alternatives to Relive Depression (STAR*D), the largest 
antidepressant trial ever [5, 6]. A main reason for this is the  
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still incomplete knowledge about the pathogenetic mecha-
nisms of depression and about the inner actions of available 
antidepressants [3]. Also, a non-dimensional, categorical 
approach [7] may lead to the use of a single diagnosis to  
include heterogeneous clinical pictures, therefore leading to 
a non patient-tailored psychopharmacotherapy. Additionally, 
even when effectiveness is well-documented, current anti- 
depressants may be associated with impairing side-effects 
which may account for most of the discontinuation cases   
[8]. 
  These considerations prompt for a better recognition and 
for an adequate clinical management of depression but also 
for the development of more selective and new-targeting 
drugs.  
  First Generation Antidepressants (FGAs) include Mono-
amine Oxidase Inhibitors (MAOIs) and Tricyclic Antide-
pressants (TCAs, 60s), while Second Generation Antidepres-
sants (SGAs, 80s-90s) include Selective Serotonin Reuptake 
Inhibitors (SSRIs), Norepinephrine and Serotonin Reuptake 
Inhibitors (SNRIs), Norepinephrine Reuptake Inhibitors 
(NARIs), Norepinephrine and Specific Serotonergic Antide-
pressants (NASSAs) and Serotonin 5-HT2A  Antago-
nists/Reuptake Inhibitors (SARIs) [3]. SSRIs still represent 
the most currently prescribed antidepressant class of drugs, 
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  Both the FGAs and SGAs are monoamine-based antide-
pressants. New monoamine-based antidepressants are cur-
rently in development or marketed, and they include 5-HT4 
and 5-HT6 agonists as well as 5-HT7 antagonists [3]. Accord-
ing to the monoamine hypothesis of depression, monoamine-
based antidepressants have been hypothesized to increase the 
synaptic availability of monoamines (which could be de-
creased in course of depression). Yet, this hypothesis of de-
pression has been criticized since it was evident that in-
creased availability of monoamines induced by antidepres-
sants develops in a matter of hours with the therapeutic ef-
fect onset only after a mean lag-phase of several weeks [17]. 
Therefore, in the following decades, new non-monoamine-
based antidepressants have been studied. They include the 
NK-1 receptors antagonists, CRF1 antagonists and the glu-
tamatergic agents (NMDA blockers, AMPAkines, mGlu 
modulators, riluzole, lamotrigine) [3]. 
AGOMELATINE: A NOVEL APPROACH TO   
DEPRESSION 
  Recently, a novel approach to depression, focusing on 
circadian rhythms, has been the basis for the development of 
agomelatine (N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide 
or S-20098), a melatonin (MT) analogue drug with a entirely 
new mechanism of action [18]. 
  In mammals, changes in the sleep-wake cycle and in the 
periodicity of circadian rhythm profoundly influence the 
state of mood, which they have already been proposed as 
candidate markers [19, 20]. Likewise, it has been shown that 
manipulations of circadian rhythms, such as a total of REM 
sleep deprivation or phase advance in the sleep-wake cycle, 
may have antidepressant action. This has also been consid-
ered the rational for complementary or alternative strategies 
such as the “sleep deprivation therapy” and similar ap-
proaches [21]. Anyway, since studies demonstrated possible 
persistent sleep changes in the remission phase of depres-
sion, it is unclear whether it is a causative factor or part of 
the clinical picture [22]. Possibly, this may be also due to an 
incomplete action of antidepressant therapy, since currently 
available drugs may be unable to address the sleep depres-
sive symptomatology. To date, agomelatine, represents the 
only available MT1/MT2 melatonergic receptors agonist and 
5-HT2C antagonist (SAR), shown to induce resynchroniza-
tion of circadian rhythms and antidepressant action in hu-
mans, [23, 24]. By avoiding 5-HT2A stimulation, agomelatine 
shows a more favorable side-effect profile compared SSRIs, 
concerning sexual functioning, weight-gain (drugs blocking 
the 5-HT2C and histamine receptors are usually associated 
with weight-gain although 5-HT2C per se shouldn’t be nec-
essarily associated with this effect) and Gastro-Intestinal 
(GI) disturbances, without exhibiting discontinuation symp-
toms [11, 18, 25-27]. 
METHOD 
  To identify relevant articles for this review, searches of the 
online databases MEDLINE and EMBASE were conducted 
using combinations of the search terms “agomelatine”,   
“melatonin”, “S20098”, “antidepressant”, “efficacy”, “safety”, 
“pharmacokinetic”, “pharmacodynamic”, “receptor binding”, 
“depression”, “Major Depressive Disorder” (MDD), “Bipolar 
Disorder” (BPD), “Seasonal Affective Disorder” (SAD), “At-
tention Deficit Hyperactivity Disorder” (ADHD) and “anxiety 
disorders”. Additional articles were identified scanning the 
reference lists of the retrieved articles. All English-language 
articles reporting original data related to agomelatine for major 
depression were included in this review while just RCT, non 
antidepressant-related agomelatine references were prioritized. 
Most relevant pre-clinical and clinical studies about 
agomelatine have been reported in Tables 1, 2 respectively. 
PHARMACOKINETICS 
  In humans, agomelatine is well absorbed following oral 
administration, but absolute bioavailability is relatively low 
(about 5-10%) due to its high first-pass metabolism [28], 
which may be considered in special populations such as the 
elderly or hepatic disordered patients. When given as a sin-
gle 25- or 50mg amount, blood concentrations increased 
more than proportionately to the dose, possibly due to satura-
tion of first-pass metabolism. Agomelatine has also moderate 
distribution in humans, with a volume of distribution of ap-
proximately 35 L., and is 85-95% bound to plasma proteins 
(again, this could taken in account prior prescription in spe-
cial populations) [29]. Agomelatine appears to be exten-
sively metabolized by the cytochrome P450 isoforms 1A1, 
1A2 and 2C9 (majority of psychiatric medications undergo 
2D6 or 3A4 or 1A2) to hydroxyl, desmethyl and epoxide 
metabolites with less activity than the parent drug. A major 
oxidative metabolite in humans, 3-hydroxy-7-desmethyl-
agomelatine, has low affinity for MT1, MT2 and 5-HT2C re-
ceptors. The drug is eliminated mostly by urinary excretion 
of the metabolites (61-81% of dose in humans), with a small 
amount of the diol metabolite undergoing fecal excretion; the 
mean terminal elimination half-life is 2.3 hours [30].  
PHARMACODYNAMICS 
  Agomelatine acts as a MT1 and MT2 agonist (reported to 
act as a partial agonist on the MT receptors in the pars tuber-
alis of the rat) [31] and as a 5-HT2C and 5-HT2B serotonin (5-
hydroxytryptamine, 5-HT) antagonist [32]. Blockade of 5-
HT2C receptor, a subtype of 5-HT that binds the endogenous 
5-HT neurotransmitter being a Gq/G11 protein-coupled recep-
tor (GPCR) mediating excitatory neurotransmission [33], 
causes release of both Norepinephrine (NE) and Dopamine 
(DA) at the frontocortical dopaminergica and adrenergic 
pathways [32] by different classes of drugs including the 
SSRI fluoxetine and norquetiapine, the principal metabolite 
of the atypical antipsychotic quetiapine [34, 35].This is why 
these agents could be called Norepinephrine and Dopamine 
Disinhibitors (NDDIs) as coined by Millan (2003) [36], act-
ing across the peripheral and brain Central Nervous System 
(CNS) including the striatum, prefrontal cortex, nucleus ac-
cumbens, hippocampus, hypothalamus, amygdala, and many 
other areas [37]. The profile of pharmacological actions pre-
dicts not only antidepressant actions due to the NDDI 
mechanism of 5-HT2C antagonism [38] (interestingly, studies 
on 5-HT agonists as potential antidepressant drugs were dis-
continued within the recent years [39]),but also sleep-
enhancing properties due to MT1  and MT2 potent agonist 
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Table 1.  Agomelatine in Mood and Anxiety Conditions and More. Current Literature Evidences in Pre-Clinical and/or Animal 
Model Studies 
Author, Date   Sample  Condition  Method  N  Subjects   Dose/Range  Results 
Table 1 part a 
Conboy et al., 
(2009) 
Animal 
model  
(murine) 
RAWM stress-
induced memory 
impairment 
RAWM stress-model:  
4 arms: vehicle-no  
stress, vehicle-stress, 
agomelatine-no-stress  
& agomelatine-stress 
20 adult caves, 4 
groups (5 sub-
jects each) 
Agomelatine 10mg/kg or 
vehicle 1mg/kg 1% 
hydroxyethylcellulose 
Agomelatine blocked the 
predator stress-induced 
impairment of spatial  
memory. Both stressed and 
non-stressed agomelatine-
treated rats showed an  
increase in the ventral  
hyppocampal expression  
of synaptic Neural Cell 
Adhesion Molecule (NCAM) 
Gressens et al. 
(2008) 
Animal 
model  
(murine) 
Periventricular  
leukomalacia and 
cerebral palsy model 
(induced by ibotenate 
injections) 
Intracerebral injection in 
newborn mice of ibotenate 
(glutamate analogue) to  
develop human periventricular 
leukomalacia. Melatonin 
(already shown to have  
neuroprotective effects in 
mouse model) was compared 
to agomelatine to investigate 
the neuroprotective effects of 
the latter drug. 
Swiss pups  
(unspecified 
number) 
10μg ibotenate were 
injected into developing 
mouse brains, inducing 
glutamate NMDA and 
metabotropic receptors 
activation. 
Although agomelatine and 
melatonin did not prevent the 
initial appearance of white 
matter lesions, they did 
promote secondary lesions 
repair when given within  
the first 2h following the 
excitotoxic insult (up to 8h 
later for agomelatine) 
BertainaAn-
glade et al. 
(2006) 
Animal 
model  
(murine) 
Animal learned 
helplessness model 
Stress response levels were 
recorded after pretreatment 
with agomelatine, melatonin, 
SB-242084 (selective 5-HT2c 
antagonist) or agomelatine + 
S22153 (melatonin receptor 
antagonist), compared to 
imipramine  
40 (10 per group) 
wistar rats 
Agomelatine 2, 10, 50, 
100 mg/kg; melatonin 2, 
10, 50 mg/kg; SB-
242084 0.31, 1.25, 5, 20 
mg/kg; S22153 20 
mg/kg; imipramine 64 
mg/kg  
Pretreatment with 
agomelatine, as with  
imipramine, decreased the 
number of escape failures, 
reflecting an antidepressant-
like properties 
Loiseau et al. 
(2006) 
Animal 
model  
(murine) 
Animal model of 
anxiety 
Rats behavior was monitored 
in the punished drinking test, 
the safety signal withdrawal 
operant paradigm, the  
elevated plus maze and  
hypophagia-induced novelty, 
after the administration of 
agomelatine or melatonin or 
agomelatine+diazepam or 
melatonin+diazepam  
Unspecified n.  Agomelatine 20-40 
mg/kg; melatonin 20-
80mg/kg; diazepam 0.25 
mg/kg 
Agomelatine displayed a 
pattern of anxiolytic activity 
on its own (increasing the 
number of foot shocks  
received by rats, but non 
enhancing food consumption 
in unfamiliar environment); 
furthermore it potentiated  
the anxiolytic effects of 
diazepam; melatonin was  
less active  
Papp et al. 
(2006) 
Animal 
model  
(murine) 
Elevated plus maze, 
vogel, conditioned 
footshock-induced 
ultrasonic  
vocalization tests. 
Monitoring of rats after  
the morning and evening 
administration of agomelatine, 
melatonin, diazepam,  
buspirone or vehicle in anxi-
ety model caves 
16 (8+8)  
wistar rats + 8 
sprague-dawley 
rats 
Agomelatine 10, 20, 50, 
75, 100, 125 mg/kg; 
melatonin 10, 20, 50 and 
75 mg/kg;  
diazepam 2.5 and 5.0 
mg/kg; buspirone 2.5 
mg/kg; vehicle (1% 
hydroxyhethylcellulose) 
1 ml/kg 
Agomelatine displayed a 
pattern of anxiolytic activity 
resembling that of diazepam 
(but without sedative  
properties) and buspirone, 
while melatonin was  
far less active 
 290    Current Neuropharmacology, 2010, Vol. 8, No. 3  Fornaro et al. 
Table 1. contd…. 
Author, Date   Sample  Condition  Method  N  Subjects   Dose/Range  Results 
Table 1 part b 
Loiseau et al. 
(2005) 
Animal 
model  
(murine) 
Animal model of 
depression  
(impulsive-related 
behavior) 
Rats were trained in a T-maze 
and allowed to choose  
between two magnitudes  
of reward: immediate but 
small reward (two pellets) vs. 
25-s delayed but large reward 
(ten pellets); rats behavior  
was examined after the ad-
ministration of agomelatine, 
GR205171 (substance  
P receptor antagonist) and 
melatonin, in comparison  
to positive controls  
clomipramine and  
fluvoxamine 
10 rats per group, 
wistar rats 
Agomelatine 10 and 30 
mg/kg; GR205171 10 
and 30 mg/kg;  
melatonin 3 and 10 
mg/kg; clomipramine  
8 mg/kg; fluvoxamine 
4 mg/kg; vehicle 
(tween 80) 
As clomipramine and  
fluvoxamine, agomelatine 
and GR205171 significantly 
increased the number of 
choices of the large-but-
delayed reward. These results 
suggest that agomelatine 
enhances rats tolerance to 
delay gratification, an effect 
which may reflect its ability 
to improve impulse control  
Barden et al. 
(2005) 
Animal 
model  
(murine) 
Transgenic mouse 
model of the  
neuroendocrine 
characteristics of 
depression (low 
glucocorticoid  
receptor functioning) 
Behavioral changes (porsolt 
forced swim test and elevated 
plus maze test), body  
temperature and ACTH and 
corticosterone levels were 
analyzed in transgenic mice 
after the administration of 
agomelatine, melatonin, 
desipramine or vehicle  
185 transgenic 
mice (bearing the 
glucocorticoid 
receptor antisense 
construct) and 115 
non-transgenic 
mice (controls) 
Agomelatine 10 mg/kg; 
melatonin 10 mg/kg; 
desipramine 10 mg/kg; 
vehicle (hydroxyethyl-
cellulose 1%) 
Agomelatine was effective in 
reversing the transgenic 
mouse behavioral changes, as 
well as desipramine or  
melatonin; agomelatine, but 
not imipramine, accelerated 
resynchronization of  
transgenic mouse circadian 
cycles of temperature and 
activity (this effect of 
agomelatine was more rapid 
than that of melatonin); no 
changes on concentrations of 
corticosterone and ACTH 
Millan et al. 
(2005) 
Animal 
model  
(murine) 
6 different stress-
induction models 
Anxiolytic profile of 
agomelatine was compared 
with clorazepate and 
SB243,213 (selective 5-HT2c 
receptor antagonist) through a 
combined neurochemical and 
behavioral approach 
Wistar rats and 
NMRI mice, 
unspecified  
number 
Agomelatine, 0.63 to 
80 mg/kg vs. melatonin 
(2.5-160 mg/kg) vs. 
SB243,213 (0.01-40 
mg/kg) vs. clorazepate 
(0.63-40 mg/kg) vs. 
vehicle 
The anxiolytic profile of 
agomelatine differs from  
that of benzodiazepines  
from which it may also  
be distinguished by its con-
trasting influence on cortico-
limbic  
monoaminergic pathways 
Tuma et al. 
(2005) 
Animal 
model  
(murine) 
Animal model of 
anxiety (social defeat) 
SCN-lesioned and non  
lesioned rats, subjected at a 
social defeat by an aggressive 
opponent  
Unspecified n.  Agomelatine – variable 
doses 
Agomelatine caused a  
clear reduction of the  
social defeat induced  
behavioral consequences 
only in the non lesioned  
rats, indicating that the 
anxiolytic -like action of 
agomelatine requires the 
integrity of the SCN 
Bourin et al., 
(2004) 
Animal 
model  
(murine) 
Animal model of 
depression 
Forced swimming-test (FTS) 
in differently treated rodents 
(rats and mice). 
10 mices per 
group (4) and 6 
rats per group (4) 
Melatonin (4, 8, 16, 32, 
64 mg/Kg) vs  
imipramine (64 mg/Kg, 
8mg/Kg), fluoxetine 
(16mg/kg). 
Antidepressant efficacy 
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Table 1. contd…. 
Author, Date   Sample  Condition  Method  N  Subjects   Dose/Range  Results 
Table 1 part c 
Hanoun et al. 
(2004) 
Animal 
model  
(murine) 
Animal model of 
depression 
Binding/electrophysiological, 
comparative study on  
the 5-HT1A modulation  
by SSRI (fluoxetine) vs 
agomelatine 
13+(5+5)+(5+5) 
rats 
Agomelatine 
10mg/kg/day vs mela-
tonin (10mg/kg/day) 
and agomelatine 
(50mg/Kg/day) vs 
fluoxetine 
(5mg/kg.day) 
Agomelatine 
Antidepressant 
effect is not related to 5-
HT1A modulation (as ex-
pected for other AD classes) 
Chagraoui et al. 
(2003) 
Animal 
model  
(murine) 
Dose-dependent 
effects of agomelatine 
in preventing penile 
erections in rats 
induced by 5-HT2c 
receptor agonists  
Penile erections were  
measured in rats after the 
injection of the 5-HT2c  
agonists ( mCPP and  
Ro 60-0175), with or without 
agomelatine (and other  
melatonin derivates) pretreat-
ment  
80-160 wistar rats  Agomelatine 1.25-40 
mg/kg; melatonin 1.25-
40 mg/kg; mCPP 0.75 
mg/kg; Ro 60-0175 2.5 
mg/kg 
Agomelatine, but not  
melatonin, dose-dependently 
decreased mCPP- and Ro 60-
0175- induced penile  
erections in rats, most  
probably due to its 5-HT2c 
receptor antagonism 
Millan et al. 
(2003) 
Animal 
model  
(murine) 
Binding affinities, in 
vivo, evaluation study 
Antagonism at 5-HT2C  
receptors and blockade  
was evaluated with in vivo 
receptor binding assays and 
measures  
Wistar rats  
(unspecified 
number) 
Agomelatine, 0.16 to 
80 mg/kg vs. melatonin 
(2.5-40 mg/kg)  
In contrast to melatonin, 
agomelatine behaves as  
an antagonist at 5-HT2c 
receptors, increasing ex-
tracellular levels of DA and 
NA in FCX and accelerating 
the firing rate of adrenergic 
cell bodies in the locus 
coeruleus; hence enhancing 
the activity of fronto-cortical 
DA-ergic and adrenergic 
pathways  
Papp et al. 
(2003) 
Animal 
model  
(murine) 
Animal model of 
depression (chronic 
mild stress) 
Sucrose test in rats subjected 
to the chronic stress procedure 
(food and water deprivation; 
45° cage tilt; intermittent 
illumination; soiled cage;  
low intensity stroboscopic 
illumination) after evening or 
morning administration of 
agomelatine, melatonin, 
imipramine, fluoxetine or 
vehicle  
336 wistar rats  Agomelatine 10 and 50 
mg/kg; melatonin 10 
and 50mg/kg; imi-
pramine 10 mg/kg; 
fluoxetine 10 mg/kg; 
vehicle (1% hy-
droxyethylcellulose) 1 
ml/kg 
Antidepressant-like activity 
of agomelatine was shown to 
be independent on the time 
of drug administration;  
the efficacy of agomelatine  
is comparable to that of 
imipramine and  
fluoxetine, but greater than 
melatonin’s one 
Tuma et al.,  
(2001) 
Animal 
model  
(murine) 
Continuous dark 
exposure with  
consequent phase 
shift in circadian 
pacemaker 
The free-running body  
temperature and activity 
rhythms were studied by 
gradual phase advances of the 
start of activity phase 
Rats (various sp.)  Agomelatine up to 
20mg/kg/day 
Agomelatine treatment 
resulted in prolonged  
overstimulation of melatonin 
receptors, attenuating the 
effects of light on the  
circadian timing system. 
Van Reeth  
et al., (2001) 
Animal 
model  
(murine) 
Age-related changes 
in circadian response 
to environmental 
stimuls 
Young and older hamsters fed 
with melatonin or its agonist 
agomelatine 
12+14 young  
(8 wk old) and 
12+14 old (10 mo) 
hamsters 
Variable doses  6 of 7 young hamsters  
fed with agomelatine  
showed large phase  
advance vs only 2  
(of 8) old controls 
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Table 1. contd…. 
Author, Date   Sample  Condition  Method  N  Subjects   Dose/Range  Results 
Table 1 part d 
Chu et al. 
(2000) 
Animal 
model  
(murine) 
Post-mortem  
evaluation of DA-
ergic and PRL act.  
on TIDA neurons 
Simultaneous determination of 
serum PRL and DOPAC levels in 
the median eminence (as indices 
for TIDA neuronal activity) in 
ovariectomized, estrogen-treated 
rats after time-dependent injections 
of melatonin, agomelatine, S-
20928 or vehicle. 
50  
sprague- 
dawley rats 
Agomelatine 1 
mg/kg; melatonin 
0.01-1 mg/kg; S-
20928 1 mg/kg 
Melatonin and agomelatine 
exerts an inhibitory effect on 
PRL secretion by stimulating 
the TIDA neurons 
Weibel et al. 
(2000) 
Animal 
model  
(murine) 
Circadian  
resynchronization in 
old hamsters after 
abrupt shifts in the 
light-dark cycle 
Running-wheel activity was  
monitored in two groups of  
hamsters (agomelatine-treated  
vs. control) subjected to an  
abrupt 8 h advance shift  
in the light-dark cycle  
(“jet-lag” paradigm)  
24 golden 
hamsters 
Agomelatine 20 
mg/kg 
Agomelatine accelerated by 
25% resynchronization of the 
circadian rhythm in hamsters 
to the new light-dark cycle 
Pitrosky et al. 
(1999) 
Animal 
model  
(murine) 
Organization of rat 
circadian rhythms 
during daily infusion 
of melatonin or 
agomelatine 
Running-wheel activity, body 
temperature and general activity 
were monitored in rats in constant 
darkness during a period of daily 
infusions of melatonin or 
agomelatine for 1, 8 or 16 h  
110 long-evans 
rats 
Agomelatine 50 and 
100 microg/h; mela-
tonin 50 and 100 
microg/h 
Agomelatine and melatonin 
entrained the free-running 
circadian rhythms of rats 
Ying et al., 
(1998) 
Animal 
model  
(murine) 
In vivo  
electrophysiological 
monitoring of SCN 
activity 
Male Syrian hamsters were  
chronically exposed to melatonin 
and agomelatine to assess  
wherever this could influence  
later response of SCN  
receptorial activity 
50 caves in four 
groups: vehicle 
(2), melatonin 
and 
agomelatine  
Agomelatine at 
1mg/kg 
Chronic SCN melatonin 
receptor exposure to 
agomelatine does not alter 
their effects on suprachias-
matic nucleus neurons 
Masson-pevet 
et al. (1998) 
Animal 
model  
(murine) 
Binding studies by 
quantitative  
autoradiography 
Record of the effects of 
agomelatine, S-20928 and  
melatonin on melatonin receptors 
in the rat pars tuberalis  
Unspecified n.  Agomelatine – 
variable doses 
Agomelatine was able to 
down-regulate melatonin 
receptors in the rat pars 
tuberalis  
Mauriño et al. 
(1998) 
Human blood 
mononuclear 
cells 
Binding studies  Binding studies and cytokine 
determinations on human blood 
mononuclear cells after the  
administration of agomelatine 
(specific membrane receptor 
agonist), CGP 52608 (RZR/ROR 
nuclear receptor agonist) and 
melatonin (membrane and nuclear 
receptors agonist) 
Unspecified n.  Agomelatine – 
variable doses 
While melatonin and CGP 
52608 increased IL2 and IL6 
production (due to their 
activity on nuclear receptor), 
agomelatine did not stimulate 
cytokine production 
Redman and 
Francis (1998) 
Animal 
model  
(murine) 
Pineal gland 
taxotomy comparative 
models  
Locomotor activity and body 
temperature rhythms were  
examined prior and after the  
injection of agomelatine or  
vehicle to assess the role of the 
suprachiasmatic nuclei (SCN)  
and of the pineal gland in the 
entrainment of circadian  
rhythms by agomelatine 
52 long-evans 
hooded rats 
Agomelatine 1-10 
mg/kg; vehicle 
(DMSO 50%) 
Entrainment of circadian 
rhythms by agomelatine 
requires intact  
suprachiasmatic nuclei  
but not the pineal gland 
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Van Reeth et 
al., (1998) 
Animal 
model  
(murine) 
Motor/ general  
activity reduction 
(depression) by dark 
prolonged exposure 
“Jet-lag” paradigms involving 
phase shifts in light-dark (LD) 
cycle, induced to investigate the 
effects of S-20098 on the circadian 
clock of diurnal rodents. 
Male Arvichan-
tis rodents 
(unspecified 
number) 
Agomelatine 
(20mg/day/kg) on 
the day of shift  
and also on subse-
quent 6h or  
8h shift paradigms. 
In each condition, 
agomelatine accelerated  
by about 30%  
resynchronization to  
the new LD cycle. 
Wiley (1998)  Animal 
model  
(murine and 
monkeys) 
Discrimination-
reinforcement test in 
rats and monkeys 
10 adult Sprague-Dawley rats and 
4 adult rhesus monkeys (Macaca 
mulatta) were trained to  
discriminate diazepam/ 
agomelatine and methohexi-
tal/agomelatine  
respectively 
10 adult rats 
and 4 adult 
monkeys 
Diazepam 2.5mg/kg 
and methohexital 
0.1mg/kg 
Subjects preferred  
diazepam or non-
melatonergic drugs to 
agomelatine, possibly  
indicating a non-addictive 
feature of the latter 
Tenn and Niles 
(1997) 
Animal 
model  
(murine) 
Modulation of rat 
dopaminergic activity 
by agomelatine 
Apomorphine-induced turning 
behavior was monitored  
in 6-hydroxydopamine  
lesioned rats, after  
administration of agomelatine, 
agomelatine+flumazenil, 
agomelatine+bicuculline or  
vehicle; competition binding 
assays (binding affinities  
of agomelatine compared  
to clonazepam,  
diazepam, and melatonin at  
benzodiazepine/GABAA  
receptors in the striatum)  
34 sprague-
dawley rats 
Agomelatine 5 
mg/kg; flumazenil 10 
mg/kg; bicuculline 
5nmol; apomorphine 
0.25 mg/kg 
Agomelatine inhibited  
apomorphine-induced  
turning In lesioned rats, 
showing an antidopaminergic 
effect (co-administration  
of flumazenil or bicuculline 
blocked this effects); 
agomelatine also inhibited 
[3H]diazepam binding stri-
atal membrane; so the anti-
dopaminergic action  
of agomelatine was mediated 
by BZ/GABAA receptors  
in the striatum 
Van Reeth  
et al., (1997) 
Animal 
model  
(murine) 
Motor/ general  
activity reduction 
(depression-like) by 
dark prolonged  
exposure  
Sleep phase in mice and  
Syrian hamsters was investigated 
by Phase-Response-Curve (PRC) 
observation. Motor activity was 
evaluated by daily wheel  
revolutions record. 
45 (dark  
exposure and 
treatment varied 
among selected 
individuals) 
Agomelatine 
(10mg/kg/day up to 
20/25 mg/Kg/day, 
respectively in mice 
and hamsters) 
Agomelatine showed dose-
dependent phase shifting 
effects on all the used  
rodents, also improving  
motor activity. 
Martinet et al. 
(1996) 
Animal 
model  
(murine) 
Wheel-running  
activity monitoring in 
rats free-running in 
constant darkness 
Dose- and concentration-  
dependent effects of  
agomelatine on entraining cir-
cadian rhythms of rats 
106 Long-evans 
rats 
Agomelatine 0.5-10 
mg/kg; melatonin 8 
mg/kg; ipsapirone 8 
mg/kg; vehicle 
(hydroxiethylcellu-
lose 1% in H2O2) 
Agomelatine was as  
effective as melatonin  
to entrain free-running 
rhythms; agomelatine 
showed dose-depended 
response from 2.5 to  
10.0 mg/kg, and also  
a clear relation between 
entrainment and plasma 
concentration  
Grassi-Zucconi 
et al. (1995) 
Animal 
model  
(murine) 
Animal model of 
dysfunction of the 
sleep regulatory 
mechanisms  
EEG recording in trypanosome- 
infected rats after administration  
of agomelatine, melatonin or 
vehicle (trypanosome infection  
in the rat reduced selectively  
the length of synchronized  
sleeps episodes)  
36 infected 
wistar rats and 
17 non-infected 
wistar rats  
Agomelatine 3 
mg/kg; melatonin 3 
mg/kg; vehicle 
(DMSO) 
Agomelatine and melatonin 
restored a normal sleep 
pattern during the infection, 
increasing the length of 
synchronized sleep episodes 
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Redman et al. 
(1995) 
Animal 
model  
(murine) 
Circadian  
resynchronization in 
rats after shifts in the 
light-dark cycle 
Using 8h phase advance paradigm, 
the effects of daily-injections of 
agomelatine on the rat activity 
rhythms were compared with those 
of melatonin 
Unspecified n.  Agomelatine 1.0-100 
mg/kg 
Agomelatine altered the 
direction of re-entrainment 
of rat activity rhythms in the 
same manner as melatonin; 
the effect was dose-
dependent, with 100% of rats 
responding at a dose of 100 
mg/kg  
Tobler et al. 
(1994) 
Animal 
model  
(murine) 
Reduced vigilance 
model in rats  
The vigilance states,  
electroencephalogram power 
spectra (0.25-25.0 Hz), and cortical 
temperature were monitored in rats 
after the administration of 
agomelatine, melatonin or vehicle 
8 rats  Agomelatine 3 
mg/kg; melatonin 3 
mg/kg 
Agomelatine and melatonin 
reduced the power density in 
non-rapid eye movement 
sleep in the low frequency 
range (1-8 Hz) but did not 
affect the vigilance states 
and brain temperature 
Armstrong  
et al. (1993) 
Animal 
model  
(murine) 
Animal model of 
delayed sleep-phase 
syndrome 
Rats were held for 3 months in 
constant darkness; when they 
returned in a light-dark cycle,  
the onset of activity lags behind  
the onset of darkness by 3-4 h;  
rats activities was monitored  
after injected with agomelatine, 
melatonin or vehicle 
24 long-evans 
rats 
Agomelatine 1 and 3 
mg/kg; melatonin 1 
mg/kg; vehicle 
(dimethylsulphoxide 
50%) 
Agomelatine and melatonin 
phase advanced the onset 
activity toward the onset of 
darkness 
 
shown to have diurnal rhythmicity, regulated by light and the 
internal clock, whereas the expression for mRNA of 5-HT2C, 
but not 5-HT1A or 5-HT2A receptors, has a circadian rhythm 
pattern in mammals [40]. 
  While functional desensitization of 5-HT1A auto-
receptors in the Dorsal Raphe nucleus (DRn) occurs after 
chronic administration of several classes of antidepressants 
and it is considered as a core mechanism implicated in the 
mood restoration, neither the acute or chronic treatment with 
agomelatine changed the density of 5-HT1A receptors and 
their coupling with G proteins in the DRn and the hippocam-
pus in rats nor in the Frontal Cortex (FC) [41]. These data 
indicate that the antidepressant action of agomelatine is not 
mediated by the same mechanisms of SSRIs and TCAs [41, 
42]. 
  Also, the DA-ergic transmission may be indirectly modu-
lated by the melatonergic one; starting with light-stimulation 
at the Pigmented Epithelium (PE) of the retina, hosting D2-
like receptors. A balance between GABA, DA and MT exists 
all over the CNS [43-47] as demonstrated by Electroreti-
nographic (ERG) studies both in health volunteers [48] and 
in course of SAD [49]. Agomelatine’ “emotional blunting”, 
due to DA direct antagonism, should therefore be hypothe-
sized. However, microdialysis studies reported dopamine 
levels in the nucleus Accumbens (ACn), a structure proven 
to be involved in course of depression in rats [50] and the 
striatum to be unaffected by agomelatine [51] whereas it 
remarkably rises at the prefrontal cortex of rats [52, 53]. The 
5-HT2C blockade also enhances the activity of FC’s DA-ergic 
and adrenergic activity, while a stimulatory and entraining 
effect of melatonin (and agomelatine) on Tubero-
Infundibular DA-ergic neurons (TIDA) activity and inhibi-
tion of Prolactin (PRL) secretion, seems to be independent 
on 5-HT2C blockade [32, 54]. 
  On a solely chronobiological basis, agomelatine should 
not behave differently from an agent like ramelteon (another 
MT1/MT2 agonist unaffecting 5-HT2C neurotransmission). 
Agomelatine, on contrast, has a dual phased action: at night, 
its sleep-promoting melatonergic effects prevail over its po-
tentially anti-hypnotic 5-HT2C blockade, whereas during the 
day, its antidepressant action via 5-HT2C inhibition is uncou-
pled from melatonin’s nocturnal actions (this may also be 
considered as an advantage of agomelatine vs. other classes 
of antidepressants) [19]. 
THE MT1/MT2 MODULATION. THE PHYSIOLOGI-
CAL MELATONERGIC BASES OF AGOMELATINE 
  Agomelatine and melatonin are not synonymous neither 
the supposed antidepressant MT1 and MT2 agonism should 
be considered in the strict sense of hormone substitutive 
modulation. On the other hand, agomelatine, next to the ex-
ogenous hormone, is the most melatonin-mimic agent devel-
oped for antidepressant therapy [55]. 
  There are three types of receptors for melatonin: 1 and 2, 
which are both involved in sleep, and 3, which is actually the 
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Goodwin  
et al., (2009) 
MDD 24-week,  placebo-controlled, 
randomized clinical trial 
339 (165 on 
agomelatine, 174 
on placebo) 
25 or 50 mg/day  Agomelatine was efficacious in preventing major 
depressive episode (MDE) recurrence while  
withdrawal syndrome was almost absent (placebo 
comparable profile) 
Kennedy  
et al., (2008) 
MDD  12 weeks double-blind, multicen-
ter study, comparison of sexual  
functioning, antidepressant 
efficacy and tolerability between 
agomelatine and venlafaxine  
137(agomelatine) 
and 140 
(venlafaxine RP) 
50 mg/day ago, 
tritated to a target 
dose of 150 mg/day 
venlafaxine 
Agomelatine showed antidepressant efficacy and a 
superior sexual side effect profile vs. venlafaxine XR 
Montejo  
et al., 2008 
Healthy  
volunteers 
8 weeks placebo-controlled study 
using PRSEXDQ-SALSEX scale 
to study sexual acceptability of 
ago compared with paroxetine 
92  25-50 mg/die ago 
20 mg/die paroxetine 
Sexual Dysfunction was sig-
nificantly lower in ago group 
than in paroxetine group 
None 
Stein et al.  
(2008) 
GAD  12 weeks randomized,  
double-blind,  
placebo-controlled trial 
121  25-50 mg/die ago  Significant superiority of ago 
25 to 50 as compared with 
placebo; clinical response, 
symptoms of insomnia and 
improvement in associated 
disability, were consistent with 
the efficacy of ago. 
Any relevant 
Calabrese  
et al., (2007) 
Depressed  
Bipolar I  
co-medicated with 
lithium or valpro-
mide 
Open-label for a minimum  
of 6 weeks followed by  
an optional extension of  
up to an additional 46 weeks 
14(lithium) 
7(valpromide) 
25 mg/day 
agomelatine 
Effectiveness of agomelatine  Any relevant 
Lemoine et al.,  
(2007) 
MDD  Placebo-controlled RCT: 2 arms, 
venlafaxine vs agomelatine 
332  25-50mg/day ago  
or 75-150mg/day 
venlafaxine  
(variable dose) 
The 6 weeks antidepressant 
effect of agomelatine was 
similar to those of venlafaxine. 
Sleep quality (measured by 
LSEQ) was subjectively better 
among patients treated with 
agomelatine. 
Few with  
venlafaxine 
(dizziness, nausea, 
vomiting, tremor 
etc…), almost any 
with ago 
Lopes et al.,  
(2007) 
Non-REM sleep 
instability in MDD 
Single-blinded  15+15  25mg/day  Agomelatine improved NREM 
sleep phases  
Out of study aims 
Montgomery  
and Kasper  
 (2007) 
Severe  
Depression 
Pooled analysis of 3 positive 
placebo-controlled studies 
357 (agomelatine) 
and 360 (placebo) 
25-50mg/day  Clearly effective  Any relevant 
Olié and Kasper,  
(2007) 
Moderate to severe 
MDD 
6 weeks, double-blind, placebo-
controlled, parallel randomized, 
group study (variably doses) 
238 25mg/day   
(augmented to 50mg/ 
day after 2weeks of 
non-response) 
Depressed and sleep items 
improved in moderate and 
severe depressed patients 
Placebo comparable 
frequency and 
severity 
Pjrek et al.,  
(2007) 
SAD  14 weeks open study  37  25 mg/day  Large percentage of patients 
experiencing sustained  
remission during the  
14 weeks of this study 
Only one adverse 
event: mild fatigue 
Quera Salva  
et al.,  (2007) 
MDD Open-label,  polysomnography 
(PSG), quantitative EEG 
15 25mg/day 
agomelatine for 6 
weeks 
Sleep efficiency increased  
and intra-sleep awakening  
progressively decreased 
Any relevant 
Kennedy and 
Emsley, (2006) 
Current (monopo-
lar) MDE 
Placebo-controlled 6 weeks RCT  212  25-50mg/day ago  Both doses resulted to be well 
tolerated and effective also in 
severe cases (50mg/day) 
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Montgomery  
et al., 
(2004) 
MDD  RCT: patients treated for 12 
weeks with paroxetine 20mg/day 
vs patients treated with ago 
25mg/day for 12 weeks, were 
abruptly discontinued to placebo 
or continued their drug for 2 
more weeks.  
192  20mg/day (paroxet-
ine) or 25mg/day 
(ago) 
Patients treated for 12 weeks with agomelatine and 
continued to 2 weeks on the same drug, showed  
similar discontinuation symptoms to those  
“continued” to placebo while the paroxetine discon-
tinued group experienced more. 
Loo et al.,  
(2003) 
DSM-III-R  
diagnosed  
MDD 
RCT  14 inpatients+14 
outpatients 
5-100mg/day ago  Acceptability, efficacy were con-
firmed both at 5 and 100mg/day 
doses. 5mg  
regimen offered best clinical 
outcome while 100mg/day resulted 
in greater side effects frequency 
and drop-outs 
Any relevant 
Loo et al.,  
(2002) 
MDD  8 weeks double-blind,  
placebo-controlled dose range 
study; paroxetine was used  
as the study validator 
711  1 mg/die or 5 mg/die 
or 25 mg/die ago 
Ago 25 mg/die is statistically more 
effective than placebo in MDD and 
alleviates the anxiety associated 
with depression. 
Any relevant 
Cajochen et al., 
(1997) 
Healthy volunteers  Cross-over design, comparison of 
acute administration of melatonin 
vs agomelatine 5h prior to bed 
time. Sleep structure and EEG 
evaluations. 
8 young male 
students  
(23-32 years) 
5-100mg/day  
(melatonin/ 
ago) 
A single early dose of melatonin or 
agomelatine increases REM sleep 
propensity and advances sleep 
termination without affecting 
NREM duration. 
None 
Kräuchi et al., 
(1997) 
Healthy volunteers  Double-blind, placebo-controlled 
crossover. Administration of 
melatonin, agomelatine and 
placebo was compared with  
dim-light onset, distal and core 
body temperature registrations. 
8  5mg/day (melatonin), 
5 or 100mg/day 
(agomelatine) 
Dose-dependent administration of 
melatonin or agomelatine resulted 
in earlier regulation of the  
endogenous circadian nocturnal 
decline in core body temperature 
and circadian phase advance. 
Out of study 
aims 
 
be involved in sleep physiology. There are several different 
agents acting at melatonin receptor sites. Melatonin itself, 
available over the counter, acts at melatonin 1 and 2 recep-
tors as well as at the melatonin 3 side. Ramelteon seems to 
provide sleep onset though not necessarily sleep mainte-
nance, being ineffective for jet lag treating [56-58], in con-
trast to the MT1/MT2 agonist tasimelteon [59], without 
modulation of the 5-HT-ergic transmission. 
  In order to assess the clinical actions of agomelatine, the 
melatonergic modulation and serotonergic one should con-
sidered separately, briefly recalling the physiologic mecha-
nisms of the hormone melatonin and, when comparative 
study have been performed, reporting a side-by-side profile 
of both. 
Synthesis of Melatonin 
  The indoleamine melatonin (N-acetyl-5-methoxytrypt-
amine) is synthesized from the amino acid tryptophan via 5-
HT synthesis. Production of melatonin by the pineal gland is 
under the influence of the Suprachiasmatic Nucleus (SCN) 
of the hypothalamus, which receives information from the 
retina about the daily pattern of light and darkness. Both 
SCN rhythmicity and melatonin production are affected by 
non-image-forming light information traveling through the 
retino-hypothalamic tract (RHT). The melatonin signal forms 
part of the system that regulates the circadian cycle by 
chemically causing drowsiness and lowering the body tem-
perature, but is the SCN that controls the daily cycle in most 
components of the paracrine and the endocrine system rather 
than the melatonin signal. The responsiveness of the SCN to 
melatonin is therefore strongly regulated by the circadian 
clock, while chronic melatonin (or agomelatine) agonism of 
the SCN melatonin receptors didn’t result in their desensiti-
zation in animal models [60]. Also, both melatonin and 
agomelatine activities on circadian rhythms depends on the 
SCN integrity but not the pineal gland as demonstrated in 
animal studies [61-63] in a dose-dependent fashion [64]. 
Aging and Melatonin 
  Under the age of 3 months, little melatonin is secreted, 
and there is no variation with light exposure. The production 
peak is reached at the age of 3 years and then this declines, 
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until around age of 40 before it fall further [65, 66]. This 
may also account for a variety of depression-related patterns 
and outcomes among different aged populations. MT and its 
receptor agonists, including agomelatine, correct age-related 
changes in circadian response to environmental stimuli in 
rodents, and could prove to be useful in treating/preventing 
or delaying disturbances of circadian rhythmicity and/or 
sleep in older people [67, 68]. 
Light and Circadian “Rhythms” 
  Production of melatonin by the pineal gland is inhibited 
by light and permitted by darkness. Hence melatonin has 
been called "the hormone of darkness" and its onset each 
evening is called the Dim-Light Melatonin Onset (DLMO). 
Secretion of melatonin, as well as its level in blood, peaks 
in the middle of the night, and gradually falls during the sec-
ond half of the night, with normal variations in timing ac-
cording to an individual's chronotype [69-71]. This justifies 
the use of melatonin, and its analogue agomelatine, to pro-
mote sleep in those with delayed sleep onset or to reset the 
internal clock that occurs with jet lag, shift working, or due 
to other causes [56, 72-74], possibly recovering from the 
Delayed Sleep-Phase Syndrome (DSPS) too [75]. Light-time 
exposure (“photoperiod”) is a pivotal element in regulating 
circadian rhythms, thus it is unsurprising that bright “light 
therapy” stimulation has already been proposed as an antide-
pressant and SAD treatment option [19, 76, 77]. 
SCN and the Anxiolytic Effect 
  Melatonin appears to have two effects on the SCN which 
are mediated either by a direct effect on the circadian rhythm 
generating cells or by activation by the GABA-ergic neurons 
within the SCN which inhibits its activity [78-80]. A GABA-
ergic modulating action, along with a 5-HT2C one, may also 
account for the reported anxiolytic effects of agomelatine 
[81-83]. While melatonin-like drugs have been reported to 
overlap the GABA agonists activity (such as diazepam), nei-
ther agomelatine nor melatonin substituted benzodiazepines 
in anxiety-stressed rats trained to discriminate the different 
drugs, suggesting that agomelatine anti-anxiety effect may 
be not as addictive as the diazepam’ one (therefore being a 
core feature when it comes to choice the proper drug in 
abusers and other addictive-behavior populations) [83-86]. 
On the other hand, agomelatine’ anxiolytic effect strictly 
resembles those of selective 5-HT2C antagonists, thus the 
melatonergic-agonism may be not entirely account for [25]. 
Efficacy of agomelatine in GAD has been reported by an 
RCT investigation by Stein et al. (2008) but further investi-
gations in PD, OCD, and other Anxiety Spectrum disorders 
are needed [87]. 
Cognitive Functions, Alzheimer’s Disease and Delirium 
  Melatonin receptors appear to be important in mecha-
nisms of learning and memory in mice [88] and the hormone 
can alter electrophysiological processes associated with 
memory, such as Long-Term Potentiation (LTP). Spatial 
visual memory, as well as the ventral hippocampal expres-
sion of the synaptic Neural Cell Adhesion Molecule 
(NCAM), were reported to improve in animal model treated 
with agomelatine [89]. 
  The first published evidence that melatonin may be use-
ful in Alzheimer's disease was the demonstration that this 
neurohormone prevents neuronal death caused by exposure 
to the amyloid beta protein, a neurotoxic substance that ac-
cumulates in the brains of affected patients [90, 91]. Mela-
tonin also inhibits the aggregation of the amyloid beta pro-
tein into neurotoxic micro-aggregates which seem to underlie 
the neurotoxicity of this protein, causing neuronal death and 
formation of neurofibrillary tangles, which are the other neu-
ropathological landmark of Alzheimer's disease [90]. Mela-
tonin has been shown to prevent the hyperphosphorylation of 
the tau protein in rats [92]. Hyper-phosphorylation of tau 
protein can also result in the formation of neurofibrillary 
tangles [92]. Studies in rats suggest that melatonin may be 
effective for treating Alzheimer's disease [92]. These same 
neurofibrillary tangles can be found in the hypothalamus in 
patients with Alzheimer's disease, adversely affecting their 
bodies' production of melatonin. Patients with this specific 
affliction often show heightened afternoon agitation, called 
“sundowning”, mainly due to cholinergic transmission. This 
phenomenon, has been shown in many studies to be effec-
tively treated with melatonin supplements taken at bedtime 
[92]. The sundowning syndrome (possibly also related to 
progressive light-decrease) often characterizes many delir-
ium cases and mood and/or cognitive disorders (especially 
when essentially due to cholinergic hypo-functioning). In-
deed, melatonergic agonism could indirectly reduce the DA-
ergic central activity and may promote the GABA-ergic ac-
tivity (therefore complicating the delirium and other cogni-
tive impairments pictures). While melatonergic drugs could 
be considered in recovering a better profile light-rhythm, 
they could carefully considered prior being administered to 
cognitive-impaired patients both in course of neuro-
degenerative diseases or when cognitive symptoms occur in 
course of depression as part of the illness or as potential con-
sequences of some antidepressant therapies, as it may occur 
with long-term treatments with SSRIs drugs. 
Melatonin and Dopamine-Related Motor Disorders 
  Inhibition of DA release by melatonin has been demon-
strated in specific areas of the mammalian CNS (especially, 
the hypothalamus, hippocampus, medulla-pons and retina) 
[93].  Anti-DA-ergic activities of MT, mediated by 
BDZ/GABAA receptors, has also been demonstrated in the 
striatum [94]. DA-ergic transmission has a pivotal role in the 
circadian entrainment of the fetus, in coordination of body 
movement and reproduction; MT may also modulate DA-
ergic pathways involved in movement disorders in humans. 
In Parkinson patients, MT may exacerbate symptoms (be-
cause of its putative interference with DA release) and, on 
the other side, protect against neurodegeneration (by virtue 
of its antioxidant properties and its effects on mitochondrial 
activity). MT appears to be effective in the treatment of 
Tardive Dyskinesia (TD), a severe movement disorder asso-
ciated with long-term blockade of the postsynaptic D2 recep-
tors induced by antipsychotic drugs (especially by first gen-
eration ones). The interaction of MT with the DA-ergic sys-
tem may play a significant role in the non-photic and photic 
entrainment of the biological clock [95] as well as in the 
fine-tuning of motor coordination in the striatum [93]. These 
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ing degenerative and possibly primary cases of rethi-
nopathies due to antipsychotic treatment [96], may also sug-
gest agomelatine and other melatonergic-drugs to be consid-
ered as potentially helpful in the treatment of DA-related 
disorders, which could also be taken into account in case of 
motor side effects eventually due to some antidepressant 
therapies as it is the case of potential extrapyramidal effects 
of SSRIs antidepressants [97]. 
MELATONIN, AGOMELATINE AND NEUROPLAS-
TICITY: PRE-CLINICAL, ANIMAL MODEL AND 
CLINICAL FINDINGS 
  Among the biological bases of depression, an impairment 
of neuroplasticity and cellular resilience has been proposed 
[98] with antidepressant medication reported contributing in 
its normalization [99-101]. Chronic stress, excess of concen-
trations of glutamate, biogenic amines and glucocorticoids 
affect the morphology of hippocampal CA3 pyramidal neu-
rons, resulting in a pronounced debranching of apical den-
drites. This affect can be blocked or counteracted by differ-
ent compounds including antidepressant drugs. 
  A 2008 study by Gressens and colleagues demonstrated 
the efficacy of agomelatine in neuroprotection and neuro-
plasticity of newborn rats. White matter cysts (mimic human 
periventricular leukomalacia), previously induced by intrape-
ritoneal injection of glutamatergic-like agents (ibotenate), 
partially recovered with melatonin (administered 2h within 
acute lesion) and agomelatine (up to 8h after) [102]. Neuro-
cognitive and antidepressant actions have also been demon-
strated in “depressed” rodents (using the Forced Swimming 
Test (FST)) comparing agomelatine vs. imipramine or vs. 
melatonin or vs. fluoxetine [103], while mice circadian sys-
tem was also proved to improve with agomelatine therapy 
(using the Phase Response Curve (PRC) record) as long as 
motor activity initiative (using the daily wheel revolution 
Chronobiology Kit
®) [20, 104]. Agomelatine treatment also 
resulted in prolonged overstimulation of melatonin receptors, 
thus attenuating the effect of light on the circadian timing 
system [105]. 
MELATONIN, AGOMELATINE AND MOOD: A   
FASCINATING CONNECTION MEDIATED BY   
CIRCADIAN RHYTHMS 
  Profound disturbances in sleep architecture often occur in 
MDD and Bipolar Disorders (BPDs) [19]. MDD with Mel-
ancholic features is associated with sleep-awake phases ad-
vance, often showing up with praecox final awake and re-
duced REM latency. MDD with seasonal patterns (MDDSP) 
is clinically characterized by depressed mood occurring at 
almost the same time every year since the disorder is first 
experienced [106]. US prevalence has been estimated to be 
at least 5% among general population with F:M ratio of 
about 5:1 [107]. Since most of the world population is   
located further from the equator, more people could be   
affected, prompting for a better comprehension of the   
phenomenon. The pathophysiology of MDDSP is not fully 
understood, although it is assumed to be associated with   
altered circadian rhythms. Basic circadian rhythms are regu-
lated by several endogenous or exogenous pacemakers, 
which major endogenous one is probably located in the   
hypothalamus. One of the major exogenous pacemakers is 
the light–dark cycle, in which different durations of light or 
dark hours affect the timing of sleep induction, hormone 
secretion, and many other biological rhythms. In health, 
euthymic subjects, the ratio of light to dark hours triggers the 
SCN to induce certain activities, including sleep, hormone 
secretion, and the secretion of melatonin (which may only 
serve as a marker associated with changes related to 
MDDSP) via stimulating the pineal gland. MDDSP is char-
acterized, among other things, by a basic state of “phase-
delay” circadian rhythm. This means that the same triggered 
activities (by the SCN) are induced at a later time in the day 
(24-hour clock) than in non-MDDSP patients. Empirical data 
suggest that when a person is exposed to bright light during 
the light hours, the SCN is stimulated to induce its activities 
at an early time in the 24-hour cycle. This is termed ‘phase-
advance’ circadian rhythm. If it is administered to a MDDSP 
patient, the ‘phase-advance’ is superimposed on a “phase-
delay” status, which may bring the system to an equilibrium, 
normalizing circadian rhythms, and at the same time amelio-
rating the depressive symptoms of MDDSP [108-110], Fig. (1). 
Melatonin, Agomelatine and Bipolar Spectrum Disorders 
  Melatonin has been considered for BPD, SAD, and other 
clinical pictures where circadian disturbances are involved 
[111, 112] as well other stress-related conditions. About 20 
years ago Ehlers et al. articulated the hypothesis concerning 
the way in which stressful life events that disrupt an individ-
ual’s normal routines (“social zeitgebers”) could initiate a 
cascade that – in vulnerable subjects – might lead to an epi-
sode of depression or mania [113]. Among psychiatric ill-
nesses, BPD is second only to unipolar depression as a cause 
of global disability [114] and may largely go under-
diagnosed [115]. Symptomatic patients with BP-I disorder 
experience depressive symptoms three to four times more 
than manic symptoms [116, 117] and symptomatic patients 
with BP-II disorder experience depressive symptoms ap-
proximately 39 times more than hypomanic ones [118]. 
These considerations prompt for a better recognition and 
management of depressive states associated with BPD and 
their clinical features. It has been observed that BPD might 
have a "trait marker" of hypersensitivity of the melatonin 
receptors [119]. Anyway, this could be contrasted with drug-
free recovered bipolar individuals not showing light hyper-
sensitivity [120]. A comprehensive review by Gao et al. 
(2005) focused on RCT studies of newly introduced drugs 
(including agomelatine) for the acute and long-term treat-
ment of bipolar depression. Preliminary open-label observa-
tions of agomelatine addiction to lithium or valproate in the 
treatment of bipolar depression showed the efficacy of the 
melatonergic drug at doses of 25mg/day after 6 weeks of 
augmentation treatment. Anyway these results need RCT 
confirmations [121]. 
  The nature of disruption of melatonin secretion in MDD 
has been under intensive study ever since it has been pro-
posed as “low melatonin syndrome” [122] and replicated by 
a number of studies [19], whereas there is no evidence of 
agomelatine increasing the levels of melatonin. However, 
increases in melatonin secretion in depressive symptomatol-
ogy has also been reported [123]. The differences could be A Systematic, Updated Review on the Antidepressant Agomelatine  Current Neuropharmacology, 2010, Vol. 8, No. 3    299 
due to changes in depressive symptomatology or to the pat-
tern of melatonin secretion, inasmuch as there are studies 
showing that daytime melatonin secretion in depressives is 
increased [19, 124]. Interestingly, lower levels of illumina-
tion in post-menopausal women have been reported to be 
associated with more complaints of sleep and depressive 
symptoms [125] whereas post-partum depression was al-
ready suggested as a possible marker/predictor of bipolar 
depression [126]. Bright light treatment of women suffering 
from ante-partum depression advanced the rhythm of mela-
tonin secretion and also mitigated depressive symptoms [19]. 
Also, a marked reduction in sleep during the night immedi-
ately before switching from depression to mania was noted 
in bipolar depressed patients [127]. 
  Yet, measurement of melatonin levels has shown signifi-
cantly lower levels in unipolar and bipolar depressed patients 
[128]. The significance of the association of sleep distur-
bances and melatonin levels in bipolar depressed patients is 
still far away from a satisfactory knowledge. 
Melatonin, Agomelatine and Major Depression 
  Both animal and human studies demonstrated agomela- 
tine to be an effective treatment for MDD [38, 81, 129-132]. 
The efficacy of agomelatine in severe depression [133, 134] 
has been investigated by Montgomery and Kasper (2007) by 
a pooled analysis of 3 positive placebo-controlled studies 
(doses were 25 to 50mg/die) proving it to be an effective 
treatment [135]. Sleep abnormalities in depression are 
mainly characterized by increased Rapid Eye Movements 
(REM) sleep and reduced Slow-Wave Sleep (SWS) [40] 
with most of available antidepressants (including TCAs and 
SSRIs) causing REM sleep suppression and increasing in 
REM sleep onset latency [136, 137]. Decreased cholinergic 
activity and increased 5-HT-ergic one are the two main fac-
tors affecting REM sleep suppression [40]; the decrease in 
amount of REM sleep appears to be greatest during the early 
phases of treatment, gradually diminishing during long-term 
treatment, except after Monoamine Oxidase Inhibitors 
(MAO-I) administration when REM sleep is often absent for 
many months. Many antidepressant medications, including 
SSRIs, have repeatedly been reported to worse sleep, mainly 
due to 5-HT2 stimulation; on the other hand, excessive sleep, 
daytime sleepiness and sedation may be experienced by   
patients tacking antidepressant medications [40]. 5-HT2 
blocking antidepressants, as mirtazapine, have been shown  
to improve sleep continuity and may therefore represent a 
good option for depressed patients with marked insomnia. 
Agomelatine (25mg/day for 6 weeks) contributes to restore 
sleep architecture in depressed patients as shown by poly- 
somnography records, improving sleep quality and continu-
ity: SWS’s duration increases without modifying REM sleep 
time [138]. An RCT investigation by Lemoine et al. (2007) 
compared venlafaxine to agomelatine for subjective sleep in 
course of MDD showing a greater improvement with the 
melatonergic drug [139]. A RCT study by Kennedy et al. 
(2008), also investigated the sexual side effect profile of 
agomelatine in comparison with venlafaxine [140]. 
SAFETY AND TOLERABILITY 
  A review by Ghosh and Hellewell, (2007) evidenced the 
effect and tolerability of agomelatine in MDD [141] which 
resulted better tolerated than SSRIs and SNRIs in MDD pa-
tients treated for 4-8 weeks on doses ranging from 5 to 
100mg/day [142], including a favorable sexual functioning 
profile which is an important cause of SSRIs non-com- 
pliance [143], Table 3. As reported by Loo et al. in a 2003 
RCT investigation, agomelatine did not modify cardiovas- 
cular parameters, including ECG recordings, neither pro-
voked biological abnormalities, weight or vital signs changes; 
slightly more adverse effects and severe treatment-related 
adverse events occurred, however, in the 100mg/day group 
(i.e. nausea was generally more frequent in the paroxetine 
comparison group) [142]. RCT studies by Kennedy and 
Emsley (2006) and Olié and Kasper (2007) also confirmed 
good tolerability (similar to placebo) of 25-50mg/day of 
agomelatine [18, 144]. Montgomery et al. (2004) focused on 
discontinuation symptoms: patients abruptly switched from 
agomelatine 25mg/day (12 weeks) to placebo were compared 
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to those continuing on the same regimen, to placebo-placebo 
and also compared to paroxetine-to placebo (20mg/day for 
12 weeks) vs. paroxetine-paroxetine subjects. After one 
week, paroxetine discontinued patients experienced signifi-
cantly more discontinuation symptoms (P<0.001), compared 
to paroxetine-continuing ones. On the other side, 2 weeks 
after agomelatine cessation, patients discontinuation symp-
toms were comparable to those of the placebo group [15, 
81]. Better acceptability of agomelatine (25 and 50 mg/day) 
compared with paroxetine (20mg/day) in healthy male vol-
unteers was also assessed by an 8-week, placebo-controlled 
study by Montejo et al. (2008) [145]. A large sampled (sub-
jects=339) 24-week, double-blind, placebo-controlled RCT 
study by Goodwin et al. (2009) demonstrated agomelatine to 
prevent relapse in patients treated for MDD with no appre-
ciable withdrawal syndrome in comparison to placebo (con-
firming efficacy seen in short-term studies) [146]. Yet, de-
spite a general good tolerability profile, prescribers should 
note the requirement to conduct liver function tests (LFTs) in 
accordance with the recent guidance by the European 
Agency of Medicines (EMEA) since recent literature evi-
dences prompt for a risk for elevation of liver enzymes with 
agomelatine (although underpinning mechanism is still under 
investigation) [147-149]. Finally, a lack of literature data of 
agomelatine safety and tolerability in older, pregnant or ado-
lescent patients still exists, whereas pharmacokinetic issues 
suggest prudence in these populations. 
LIMITS 
  At writing time, a paucity of investigations about 
agomelatine antidepressant efficacy and tolerability in hu-
man samples still exists, although most of available data 
suggest its efficacy and safety at doses of 25-50mg/kg. In 
comparison to other antidepressants, the tolerability profile 
of this agent makes it a treatment option for patients who 
cannot tolerate currently available antidepressants [150]. 
  Preliminary observations on agomelatine use in de-
pressed subjects are available although its peculiar pharma-
codynamic profile suggests to explore also other conditions. 
The MT1 and MT2 agonism, as well the 5-HT2C (and 5-HT2B) 
antagonism, involve more complex neuronal firing mecha-
nisms (involving DA-ergic and GABA-ergic modulations), 
further complicating the comprehension of agomelatine’ 
biological and clinical actions. Additionally, the Hamilton 
Rating Scale for Depression (HAM-D) and Anxiety (HAM-
A), Clinical Global Impression (CGI) and Montgomery-
Asberg Depression Rating Scale (MADRS) showed signifi-
cant improvement with agomelatine vs. placebo [151, 152]. 
Possibly, the rating instruments may be inappropriate to ade-
quately assess the sleep and circadian symptoms of depres-
sion, leading to a bias in comparative studies involving 
agomelatine and other classes of antidepressant.  
CONCLUSIONS 
  Expectations from new antidepressant therapies go be-
yond efficacy alone, to include advantages in tolerability and 
safety. Although current diagnostic instruments and rating 
scales may be unable to cover the sleep disturbances of de-
pression in a proper and comprehensive manner, agomelatine 
efficacy on MDD symptoms has been pointed out by pre-
liminary observations both on pre-clinical and clinical sam-
ples. Due to its pharmacological profile, agomelatine does 
not induce the side effects related to common antidepressant 
prescriptions (i.e. gastrointestinal disorders, weight gain, 
sexual dysfunction, serotonin syndrome, insomnia, discon-
tinuation syndrome, and others) [153], making the drug an 
intriguing option in the antidepressants scenario. 
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Table 3.  Comparison of SSRIs Efficacy and Tolerability vs. Agomelatine 
  SSRIs Agomelatine 
GI disturbances  x 
[a] 0 
[c] 
Long-term weight gain  x/xx 
[a] 0 
[c] 
Daytime sleepiness  x/xx 
[a] 0 
[c] 
Sexual dysfunction 
(may be dose-related) 
xx/xxx 
[a] 0 
[c][d] 
Discontinuation symptoms  x/xx 
[a] 0/x 
[e] 
Efficacy on more severe depression  “questioned” 
[b]  Preliminary 
[f] observations reported agomelatine to be efficacious as long-term RCT evi-
dences showed its efficacy in the prevention of major depressive episode recurrence 
[g] 
[a] Masand and Gupta, 1999 
[b] Anderson, 2000; Sonawalla and Fava, 2001; Vestergaard et al., 1993 
[c] Hindmarch et al., 2000; Judge et al., 2002; Michelson et al., 2000; Rosenbaum et al., 1998; Montgomery et al., 2004 
[d] 100 mg/day regimen of agomelatine were reported to be associated with possible side effects (Loo et al., 2003) 
[e] Discontinuation cases may be related to a non satisfactory antidepressant response when a low-dose, monotherapy regimen, is established and may be comparable to placebo-
related ones (Goodwin et al., 2009) 
[f] Olié and Kasper, 2007 
[g] Goodwin et al., 2009 
Note: “0” should be clinically considered as a “placebo-comparable” profile in most of the cases A Systematic, Updated Review on the Antidepressant Agomelatine  Current Neuropharmacology, 2010, Vol. 8, No. 3    301 
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